Nuclear Medicine/ Radiopharmaceuticals Market 2020 | Industry Trends, Growth Drivers, Competitive Landscape, Regional Analysis 2026

The MarketWatch News Department was not involved in the creation of this content.

Dec 04, 2020 (The Expresswire) —
The global “Nuclear Medicine/Radiopharmaceuticals Market” size is projected to reach USD 9.67 billion by 2026. According to a report published by Fortune Business Insights, titled “Nuclear Medicine/Radiopharmaceuticals Market Size, Share and Industry Analysis, By Type (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals), By Application (Neurology, Cardiology, Oncology, and Others), By End User (Hospitals and Clinics, Diagnostic Centres, and Others) and Regional Forecast, 2019-2026,” the market was valued at USD 4.86 billion in 2018. Driven by increasing number of successful clinical trials, the market will exhibit a CAGR of 9.2% from 2019-2026.

Leading Players operating in the Nuclear Medicine/ Radiopharmaceuticals Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • Lantheus Medical Imaging, Inc.
  • Cardinal Health
  • Norgine B.V.
  • Curium
  • Advanced Accelerator Applications (Novartis AG)
  • Bracco Diagnostic Inc.
  • Jubilant Life Sciences Limited
  • Bayer AG
  • Eli Lilly and Company
  • GE Healthcare (General Electric Company)

Request a Sample Copy of the Research Report:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/nuclear-medicine-radiopharmaceuticals-market-101812

Radiopharmaceuticals are substances that are used to diagnose specific medical problems or diseases. Increasing imaging capabilities and efficiencies have led to a wide product adoption across the world. Increasing number of successful clinical trials associated with radiopharmaceuticals will fuel the demand for the product. Recent drug application area discoveries have showcased promise for the companies operating in the market. Technological advancements in nuclear imaging and their applications in diagnosis of cancer and other serious diseases have opened up a huge potential for growth. Growing awareness regarding the adverse effects of chronic diseases, and the need for early diagnosis will aid market growth.

The advancements in imaging systems have played a major role in the growth of the market. Companies are putting in increased efforts towards the manufacturing of diagnostic radiopharmaceuticals. Increasing investments in the research and development (RandD) will create several growth opportunities for market growth. At the same instance, therapeutic radiopharmaceuticals can be used for the treatment of critical illnesses such as cancers.

Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/nuclear-medicine-radiopharmaceuticals-market-101812

Detailed Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Installed Base of PET/PET-CT Scanners For Key Countries, 2015 and 2018
    • Installed Base of Gamma Cameras for Key Countries, 2018
    • PET/PET-CT Procedure Volume for Key Countries, 2018
    • Reimbursement Scenario in Key Countries
    • New Product Launches
    • Key Industry Developments
    • Pipeline Analysis
  • Global Nuclear Medicine/ Radiopharmaceuticals Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast By Type
      • Diagnostic Radiopharmaceuticals
        • PET Radiopharmaceuticals
          • FDG-PET/18F
          • 68Ga
          • 68Cu
          • 11C
          • Others
        • SPECT Radiopharmaceuticals
          • Technetium-99m
          • Iodine-123
          • Xenon-133
          • Thallium-201
          • Others
        • Therapeutic Radiopharmaceuticals
      • Market Analysis, Insights and Forecast By Application
        • Neurology
        • Cardiology
        • Oncology
        • Others
      • Market Analysis, Insights and Forecast By End User
        • Hospitals and Clinics
        • Diagnostic Centers
        • Others
      • Market Analysis, Insights and Forecast By Region
        • North
Read more

Global Ayurvedic Medicine Market Size by Regional Industry Growth, Statistics & Forecast by 2025

The MarketWatch News Department was not involved in the creation of this content.

Nov 26, 2020 (Market Insight Reports) —
Selbyville, Delaware, MarketStudyReport.com offers report on Global Ayurvedic Medicine Market that evaluates industry growth trends through historical data and estimates prospects based on comprehensive research. The report extensively provides the market share, growth, trends and forecasts for the period 2020 – 2025.

The global Ayurvedic Medicine market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 11.4% in the forecast period of 2020 to 2025 and will expected to reach 7331.5 million by 2025, from 4754.3 million in 2019.

The Ayurvedic Medicine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Request a sample copy of this report at:

https://www.marketstudyreport.com/request-a-sample/2468922/?utm_source=Marketwatch.com&utm_medium=SK

Main Objectives of this Global Ayurvedic Medicine Marketstudy:

To provide detailed information regarding the major factors (drivers, restraints, opportunities, and challenges) influencing the growth of the Global Ayurvedic Medicine Market.

To strategically analyze the Micro markets with respect to individual growth trends, Prospects, and Contributions to the total market.

To analyze opportunities in the overall Global Ayurvedic Medicine Market for stakeholders by identifying the high growth segments.

To describe and forecast the overall Global Ayurvedic Medicine Market, in terms of value, segmented based on type, and application.

To forecast the market size for various segments, by key region.

The Global Ayurvedic Medicine Market spans across five major geographies: North America, Latin America, Europe, Asia-Pacific and the Middle East and Africa.

To analyze opportunities in the overall Global Ayurvedic Medicine Market for stakeholders by identifying the high growth segments.

To profile key players and analyze their Market ranking in terms of revenues and core competencies and provide details of the competitive landscape for the Global Ayurvedic Medicine Market leaders.

To analyze growth strategies such as Contracts, Mergers and Acquisitions, Product launches and Developments, and Research and Development in the overall Global Ayurvedic Medicine Market.

Segmentation of Global Ayurvedic Medicine Market:

Ayurvedic Medicine market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Ayurvedic Medicine market has been segmented into:

Health Care

Oral Care

Hair Care

Skin Care

Others

By Application, Ayurvedic Medicine has been segmented into:

Women

Men

Kids

key Companies covered:

Patanjali Ayurved Limited

Vicco Laboratories

Himalaya Drug

Dabur

Shahnaz Husain Group

Emami Group

Charak Pharma

Baidyanalh

Maharishi Ayurveda

Amrutanjan Healthcare

Botique

Natreon

Herbal Hills

Basic Ayurveda

Main reasons for the purchase:

To obtain insightful analysis of the Global Ayurvedic Medicine Market and a comprehensive understanding of

Read more

A promotion and awards for Lakeview Regional Medical Center, Slidell Memorial | St. Tammany community news

Lakeview Regional Medical Center, a campus of Tulane Medical Center, has promoted Tilly Gard to its trauma program director role.

Gard has been with Lakeview Regional since 2012, serving most recently as trauma program manager. Under her leadership, Lakeview Regional achieved the first Level III ACS Trauma Verification in the state with no deficiencies, a Lakeview spokeswoman said.

Gard was the recipient of the Frist Humanitarian Award in 2018 for Lakeview Regional and HCA MidAmerica Division. She was also honored in 2012 as a Great 100 Nurses of Louisiana. Gard earned prior clinical experience from hospitals all over the southeastern region of Louisiana. 

“A critical component of our trauma program is leadership, and as we progress on our trauma journey and advance trauma care in our region, I cannot think of a more qualified leader than Tilly Richard-Gard,” said Hiral Parel, Lakeview Regional CEO. “Tilly has led many significant components of our program — performance improvement, community outreach and research, to name just a few.

“I look forward to the future of our trauma program — it is in excellent hands with Tilly Gard, Dr. Marco Hidalgo and the entire team.”

She is a native of Louisiana and attended Nicholls State University College of Nursing. She received her nursing degree from University of Southwestern Louisiana College of Nursing in Lafayette. She is a member of the Louisiana State Nurses Association, American Nurses Association, Emergency Nurses Association, Louisiana Emergency Nurses Association, American Trauma Society, Society of Trauma Nurses, and American Society of Perioanesthesia Nurses.

For more information about Lakeview Regional, please visit lakeviewregional.com or call (985) 867-380

Slidell Memorial applauded for commitment to stroke care

Slidell Memorial Hospital has received the American Heart Association/American Stroke Association’s Get With The Guidelines-Stroke Gold Plus Quality Achievement Award.

The award recognizes the hospital’s commitment to ensuring stroke patients receive the most appropriate treatment based on nationally recognized, research-based guidelines based on the latest scientific evidence.

Slidell Memorial earned the award by meeting specific quality achievement measures for the diagnosis and treatment of stroke patients at a set level for a designated period.

These measures include evaluation of the proper use of medications and other stroke treatments aligned with the most up-to-date, evidence-based guidelines with the goal of speeding recovery and reducing death and disability for stroke patients. Before discharge, patients also receive education on managing their health, get a follow-up visit scheduled, as well as other care transition interventions

The hospital also received the Association’s Target: Type 2 Diabetes Honor Roll award. To qualify for this recognition, hospitals must meet quality measures developed with more than 90% of compliance for 12 consecutive months for the “Overall Diabetes Cardiovascular Initiative Composite Score.”

Additionally, Slidell Memorial met specific scientific guidelines as a Primary Stroke Center, featuring a comprehensive system for rapid diagnosis and treatment of stroke patients admitted to the emergency department.

“We are pleased to recognize Slidell Memorial for their commitment to stroke care,” said Lee H. Schwamm, M.D., national chairman of the Quality Oversight

Read more

VitalHub Continues to Increase NHS UK Presence with Additional Regional Licensing Deal of Synopsis Products

TORONTO, Oct. 28, 2020 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the licensing of newly-acquired subsidiary Intouch With Health’s (“Intouch”) digital, at-home pre-op solutions, Synopsis iQ, to Northumbria Healthcare NHS Foundation Trust (“Northumbria” or the “Trust”).

Northumbria Healthcare NHS Foundation Trust has licensed VitalHub subsidiary Intouch’s digital pre-operative solution platform, Synopsis iQ, as the Trust launches a new digital pre-operative assessment (POA) pathway that will improve demand and capacity planning and resource utilization, helping to fill last-minute surgery slots and reducing the number of face-to-face appointments the department processes.

The Synopsis solution will enable Northumbria to meet a number of Trust targets, such as reducing the face-to-face appointments, which has become a much-needed requirement in the pandemic climate. Synopsis will provide the Trust with tools to afford patients with an improved experience leading up to surgery, affecting both the delivery and quality of care provided.

The project is part of the Trust’s drive to create a more efficient operating room booking pathway by creating a pool of ‘pre-op ready’ patients’ consultants can use to create operating room lists and fill last-minute surgery slots. As part of the project, patients waiting for surgery will also be able to complete their POA health questionnaire at home via a secure link on the Trust’s website. Results are then sent to the Trust’s pre-operative assessment department where staff can triage and swim-lane patients into the correct fitness and readiness categories.

The Trust identified a considerable burden on pre-op assessment departments, facing high volumes of last-minute requests for patient appointments, resulting in operating time delays and resource inefficiencies. Prior to the COVID-19 pandemic, the Trust established a target to reduce the number of face-to-face appointments patients had to attend, creating a need for a pre-op pathway solution, and has selected Synopsis iQ and Synopsis Home as their solutions of choice to enable the progression of this target.

Digitizing the pre-operative assessment process will also allow consultants and anaesthetists to access full patient notes from any of the Trust’s four hospital sites. The project will be rolled out across North Tyneside General Hospital, Northumbria Specialist Emergency Care Hospital, Hexham General Hospital and Wansbeck General Hospital, giving staff across all four hospitals secure access to patient records and a real-time view of each patient’s status through the pre-operative pathway.

Northumbria Healthcare NHS Foundation Trust is a regional healthcare network that provides a range of health and care services to support more than 500,000 people living in Northumberland and North Tyneside. The Trust delivers care from 11 sites, including their emergency care hospital, general and community hospitals, outpatient and diagnostic centers, an elderly care unit and an integrated health and social care facility. The Trust admitted over 116,000 patients and handled over 368,000 outpatient appointments in the 2017/18 period.

“We are seeing an aggressive uptick in awareness and interest in the Synopsis suite of products,” said Dan Matlow, CEO of VitalHub Corp. “With this contract, we add another

Read more